The Goldman Sachs Group Lowers UroGen Pharma (NASDAQ:URGN) Price Target to $3.00

UroGen Pharma (NASDAQ:URGN) had its target price cut by The Goldman Sachs Group from $16.00 to $3.00 in a report released on Thursday morning,Benzinga reports. They currently have a neutral rating on the stock.

Other equities research analysts have also issued reports about the stock. LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price objective for the company. D. Boral Capital restated a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a report on Thursday, May 8th. Scotiabank assumed coverage on shares of UroGen Pharma in a report on Wednesday, April 16th. They set a “sector outperform” rating and a $23.00 price target for the company. Guggenheim reiterated a “buy” rating on shares of UroGen Pharma in a report on Tuesday, April 29th. Finally, HC Wainwright reiterated a “neutral” rating on shares of UroGen Pharma in a report on Thursday. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $31.00.

UroGen Pharma Trading Down 2.2%

Shares of URGN opened at $4.08 on Thursday. The firm has a market cap of $188.12 million, a price-to-earnings ratio of -1.30 and a beta of 0.66. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. UroGen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $20.70. The firm has a 50 day moving average price of $10.18 and a 200-day moving average price of $10.73.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The firm had revenue of $20.25 million for the quarter, compared to analysts’ expectations of $22.71 million. As a group, equities research analysts forecast that UroGen Pharma will post -3.12 earnings per share for the current year.

Institutional Investors Weigh In On UroGen Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in URGN. CWM LLC increased its position in UroGen Pharma by 6,047.1% during the 1st quarter. CWM LLC now owns 5,225 shares of the company’s stock valued at $58,000 after purchasing an additional 5,140 shares during the period. KLP Kapitalforvaltning AS purchased a new position in UroGen Pharma during the 4th quarter valued at $59,000. Lazard Asset Management LLC purchased a new position in UroGen Pharma during the 4th quarter valued at $67,000. GAMMA Investing LLC increased its position in UroGen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company’s stock valued at $83,000 after purchasing an additional 7,392 shares during the period. Finally, Aquatic Capital Management LLC purchased a new position in UroGen Pharma during the 4th quarter valued at $101,000. 91.29% of the stock is currently owned by institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.